CORRECTION: The Global Virus Network (GVN) Escalates MPOX Emergency Response Across Africa and Beyon
The GVN MPOX Action Committee is poised to mobilize resources and catalyze efforts in the urgent global call to action
TAMPA, Fla., Sept. 02, 2024 (GLOBE NEWSWIRE) - A correction has been issued for the release disseminated on August 16th. Sten Vermund's full title was corrected to Sten Vermund, MD, PhD, GVN President and Professor of Yale University, USA. The complete and corrected release follows.
As the World Health Organization (WHO) declares MPOX a public health emergency of international concern, the Global Virus Network (GVN), headquartered at the University of South Florida (USF), USA, swiftly orchestrated an international response to combat the rising threat. The GVN's MPOX Action Committee, formed in 2022, is led by world experts spanning basic research, epidemiology, clinical research, and vaccines. In the past several weeks, the GVN has rapidly mobilized essential resources, launched critical evaluations of diagnostic tools, and provided strategic support to the most affected regions.
Sten Vermund, MD, PhD, GVN President and Professor of Yale University, USA, said, "MPOX is a reemerging disease whose magnitude is rising at an alarming rate among general populations in Africa. Furthermore, it has shown potential for sexually associated transmission worldwide. The GVN MPOX Action Committee is working with the WHO and international partners to craft an evidence-based response and further research agenda.”
Since last week's announcement that MPOX was reported in countries never previously identified with cases, the GVN partnered with the UK Health Security Agency (UKHSA) and multiple African institutions through its members to assess point-of-care (POC) tests for MPOX, ensuring these diagnostics are accurate, accessible, and deployable in various environments.
Emma Thomson, PhD, Professor of Infectious Diseases and Associate Director, Medical Research Council-University of Glasgow Centre for Virus Research, UK, a GVN Center of Excellence, added, "GVN's coordinated response exemplifies the power of global collaboration in a public health crisis. We are proud to be part of a network that is helping to set priorities and making a real difference in the fight against MPOX. We look forward to working with the GVN, WHO, and other partners to mitigate this viral outbreak."
The GVN's MPOX Action Committee is co-led by Rachel Roper, PhD, Professor of Microbiology and Immunology at East Carolina University, USA, who expressed deep concern: "The MPOX virus appears to be evolving for more efficient human transmission, which is alarming. With 17,000 reported cases and the unprecedented spread of MPOX Clade Ib from the Democratic Republic of Congo (DRC) to neighboring countries, there is a clear need for heightened and continuous surveillance. We have vaccines that mitigate illness and death, but there is an urgent need for improved vaccines with better safety and efficacy."
Dr. Roper further emphasized the importance of therapeutics, stating, "We do have antibodies and treatments that offer some protection, but these viruses have already demonstrated the ability to rapidly develop resistance. It's critical that we expand the arsenal of therapeutic agents."
In addition to forming an MPOX Action Committee two years ago comprised of top experts, GVN's proactive measures include the deployment of 1,000 newly developed MPOX rapid tests several weeks ago to its members across Africa for immediate side-by-side evaluation. The network is also distributing new rapid test platforms for loop-mediated isothermal amplification (LAMP) assays to strategic locations, aiming to foster the development of diagnostics that can be efficiently implemented in resource-limited settings. Further, since 2022, GVN members published more than 70 scientific papers advancing MPOX research.
Laurens Liesenborghs, MD, PhD, an infectious disease specialist and researcher at the Institute of Tropical Medicine, Belgium, under the lead of Placide Mbala-Kingebeni, MD, PhD, Director of the Virology Division at the Institut National de Recherche Biomédicale (INRB), Democratic Republic of the Congo, together with others, was the first to investigate and sequence the newly identified MPOX Clade Ib variant. Dr. Liesenborghs said, "Our team remains on-site, dedicated to conducting research, and supporting surveillance and patient care. Together, we continue to combat this evolving threat and ensure the health and safety of the affected communities. Support from the GVN, which we are receiving, and other partners, is needed to address this public health crisis swiftly." Drs. Liesenborghs and Mbala-Kingebeni are members of the GVN MPOX Action Committee.
Maggie L. Bartlett, PhD, Program Director at GVN and virologist at Johns Hopkins Bloomberg School of Public Health, USA, a GVN Center of Excellence, said, “The ongoing challenges with MPOX underscore the urgent need for comprehensive global surveillance and targeted response strategies. By closely collaborating with WHO and other international partners, we ensure that our efforts are aligned and that our scientific contributions directly address the pressing challenges on the ground.”
MPOX has been detected in 13 nations this year including previously unaffected nations such as Burundi, Kenya, Rwanda, and Uganda. In 2024, thus far, The Africa Centers for Disease Control and Prevention (Africa CDC) reports that these countries have confirmed 2,863 cases and 517 deaths and growing, primarily in the Democratic Republic of the Congo (DRC). Suspected cases across the continent have surged past 17,000, a significant increase from 7,146 cases in 2022 and 14,957 cases in 2023. Officials at the Africa CDC said nearly 70% of cases in Congo are in children younger than 15, who also accounted for 85% of deaths.
GVN plays a crucial role in facilitating direct communication between its experts, WHO officials, and other international partners. Christian Bréchot, MD, PhD, Vice Chairman of the GVN Board of Directors, GVN President Emeritus and Senior Associate Dean for Research in Global Affairs at University of South Florida Health's Morsani College of Medicine, USA, highlighted the importance of the collaboration: “GVN's role to enhance global efforts is critical in identifying research gaps and facilitating action to fill those gaps. GVN is uniquely prepared to quickly engage our members and provide expertise and on-the-ground support to mitigate the growing MPOX threat. We are pleased to catalyze and facilitate alliances to prepare and protect humankind from viral threats.”
GVN's Viral Detection and Control Action Committee will convene a critical meeting on August 22 at 11 AM EDT | 5 PM CET, with WHO's MPOX Task Force lead, Lorenzo Subissi, PhD, who will provide updates and garner support from GVN experts.
About the Global Virus Network (GVN)
The GVN is essential and critical in the preparedness, defense, and first research response to emerging, existing, and unidentified viruses that pose a clear and present threat to public health. Working in close coordination with established national and international institutions, the GVN is a coalition comprised of eminent human and animal virologists from 80+ Centers of Excellence and Affiliates in 40+ countries, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines, and treatments to combat them. No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues, and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org.
For more information or to join GVN's efforts, please contact Linman Li at Linmanli@gvn.org.
- 初心不变,怡和嘉业以创新为引擎构建呼吸新生态
- 重视硒营养 力促大健康‖任玉岭在重庆硒粉文化节暨硒营养高峰论坛的讲话
- 2024嘉峪关长城马拉松暨长城联赛·嘉峪关站圆满落幕
- 胖小达影视:为国家文化产业发展注入新活力
- 可被设计的生活:顾家家居的“幸福方程式”
- 从豆种到饮品,揭开Julius Meinl小红帽咖啡高品质的面纱
- G7易流携手哒哒智运,共筑数字化物流新生态
- 以油养肤,悦元素抗皱紧致精华油震撼上市
- 国产制造,欧美品质:爱可声助听器产品质量获国际认可
- 平安人寿开展践行新时代“枫桥经验”主题党日活动 探索保险纠纷化解新思路
- 江苏省委副书记、省长许昆林一行莅临丰尚调研
- 第68届摩纳哥玫瑰慈善舞会耀眼呈现,缔造传奇!
- 农发行寿阳县支行开展“爱生活、爱自己” 三八主题活动
- Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Re
- 丹青妙手·书画双绝——书画名家张二群百家媒体聚焦报道
- 威雅学校:A Level放榜 威雅学子再获佳绩!
- Vestel 加入 HEVC Advance 专利池
- 临商银行北城支行多措并举推进节约型支行建设
- 源真沉香20年沉香领域的领军者
- 宁夏宁联智慧健康:守护青少年视力健康,点亮未来视界
- 小柯全新音乐剧《深处》用真心再创奇迹,高朋满座,好评如潮!
- 春游江淮|初夏想和你赴一场属于“皖南川藏线”的自驾约会~
- Haim Shani Concludes Tenure at Cellebrite as Company Enters Next Growth Phase
- Andersen Global通过在尼日利亚和南非加强估值能力来巩固其非洲平台
- Xsolla推出屡获殊荣的后端解决方案并为下一代游戏机提供跨平台游戏支持
- SOAR INTO THE YEAR OF THE DRAGON WITH VISTAJET
- 《中国军创集团》董事局主席高希建等慰问老兵
- PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep A
- 东莞市恒展新材料有限公司---致力打造服饰行业无缝贴合设备领军品牌
- 森马上海时装周上演“自在野出行” 携手胡兵演绎实感品质穿搭
推荐
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
- 抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯